INT 0022Alternative Names: INT-0022; INT0022/2010
Latest Information Update: 23 Dec 2013
$50 / €47 *
At a glance
- Originator IntelGenx Corp.
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bipolar disorders